Market Cap | 87.26M | P/E | - | EPS this Y | 12.90% | Ern Qtrly Grth | - |
Income | -36.24M | Forward P/E | -1.91 | EPS next Y | 4.00% | 50D Avg Chg | -14.00% |
Sales | 306k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 9.00% |
Dividend | N/A | Price/Book | 0.97 | EPS next 5Y | - | 52W High Chg | -34.00% |
Recommedations | 1.50 | Quick Ratio | 2.48 | Shares Outstanding | 31.67M | 52W Low Chg | 155.00% |
Insider Own | 17.99% | ROA | -23.51% | Shares Float | 17.09M | Beta | 1.49 |
Inst Own | 62.86% | ROE | -42.86% | Shares Shorted/Prior | 234.41K/115.76K | Price | 2.81 |
Gross Margin | 31.37% | Profit Margin | - | Avg. Volume | 27,404 | Target Price | - |
Oper. Margin | -21,580.49% | Earnings Date | - | Volume | 23,199 | Change | -5.55% |
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Citigroup | Neutral | Aug 10, 23 |
Citigroup | Neutral | Nov 10, 22 |
Oppenheimer | Outperform | Aug 29, 22 |
Berenberg | Buy | Apr 27, 22 |
Citigroup | Neutral | Mar 30, 22 |
Oppenheimer | Outperform | Nov 19, 21 |
William Blair | Outperform | Aug 9, 21 |
Citigroup | Buy | Aug 9, 21 |
Cowen & Co. | Outperform | Aug 9, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Jackson Benjamin | General Counsel General Counsel | Dec 07 | Sell | 5.22 | 10,000 | 52,200 | 157,700 | 12/07/23 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Dec 07 | Sell | 4.80 | 5,000 | 24,000 | 194,454 | 12/07/23 |
Kearney Paul | Chief Data Officer Chief Data Officer | Apr 06 | Option | 0.75 | 24,050 | 18,038 | 40,050 | 04/07/23 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Sep 08 | Option | 0.73 | 844 | 616 | 47,354 | 09/09/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jul 26 | Option | 0.73 | 1,000 | 730 | 47,510 | 07/27/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jul 26 | Sell | 2.19 | 3,725 | 8,158 | 46,510 | 07/27/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jul 19 | Sell | 1.86 | 2,725 | 5,068 | 49,235 | 07/19/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jul 05 | Sell | 1.63 | 2,725 | 4,442 | 54,685 | 07/05/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jun 28 | Option | 0.73 | 1,000 | 730 | 58,410 | 06/29/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jun 28 | Sell | 1.81 | 3,725 | 6,742 | 57,410 | 06/29/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jun 21 | Sell | 1.31 | 2,725 | 3,570 | 60,135 | 06/21/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Jun 07 | Sell | 1.30 | 2,725 | 3,542 | 65,585 | 06/07/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 31 | Option | 0.73 | 1,000 | 730 | 69,310 | 06/01/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 31 | Sell | 1.41 | 3,725 | 5,252 | 68,310 | 06/01/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 24 | Sell | 1.54 | 2,725 | 4,196 | 71,035 | 05/24/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 17 | Sell | 1.55 | 2,725 | 4,224 | 73,760 | 05/17/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 10 | Sell | 1.97 | 2,725 | 5,368 | 76,485 | 05/10/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 04 | Option | 0.73 | 1,000 | 730 | 80,210 | 05/04/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 04 | Sell | 2.17 | 1,000 | 2,170 | 79,210 | 05/04/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | May 03 | Sell | 2.17 | 2,725 | 5,913 | 79,210 | 05/03/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Apr 26 | Sell | 2.17 | 2,725 | 5,913 | 81,935 | 04/26/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Apr 19 | Sell | 2.08 | 2,725 | 5,668 | 84,660 | 04/20/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Mar 14 | Sell | 3.94 | 2,725 | 10,736 | 98,285 | 03/15/22 |
Boniface John J. | Chief Scientific Off.. Chief Scientific Officer | Mar 11 | Option | 0.73 | 75,998 | 55,479 | 101,010 | 03/14/22 |